| Dr John Harvery Turco, MD | |
|
1 Medical Center Dr, Lebanon, NH 03756-1000 | |
| (603) 650-8630 | |
| (603) 860-2240 |
| Full Name | Dr John Harvery Turco |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 50 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134143969 | NPI | - | NPPES |
| 00000197 | Medicaid | NH | |
| 0004937 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 6117 (New Hampshire) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mary Hitchcock Memorial Hospital | Lebanon, NH | Hospital |
| Alice Peck Day Memorial Hospital | Lebanon, NH | Hospital |
| New London Hospital | New london, NH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dartmouth-hitchcock Clinic | 4183537509 | 1139 |
| Mary Hitchcock Memorial Hospital | 4486561164 | 964 |
News Archive
Do school-based interventions prevent HIV, sexually transmitted diseases and pregnancy? This is the question asked by researchers from the University of York, South African Medical Research Council and Stellenbosch University in a Cochrane review published this week.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company's strategic alliance with GlaxoSmithKline.
A collaboration of French and Canadian researchers have found that sucking a portion of a spherical globule of cells into a tiny pipette provides information about the adhesion between cells and the elastic properties of the tissue. The method is a novel approach for the study of the structural properties of tissues, and should offer insights into processes such as embryonic development, tissue growth and cancer. A paper describing the research appears online in Physical Review Letters on May 24.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Entity Name | Mary Hitchcock Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023092053 PECOS PAC ID: 4486561164 Enrollment ID: O20031126000258 |
News Archive
Do school-based interventions prevent HIV, sexually transmitted diseases and pregnancy? This is the question asked by researchers from the University of York, South African Medical Research Council and Stellenbosch University in a Cochrane review published this week.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company's strategic alliance with GlaxoSmithKline.
A collaboration of French and Canadian researchers have found that sucking a portion of a spherical globule of cells into a tiny pipette provides information about the adhesion between cells and the elastic properties of the tissue. The method is a novel approach for the study of the structural properties of tissues, and should offer insights into processes such as embryonic development, tissue growth and cancer. A paper describing the research appears online in Physical Review Letters on May 24.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Entity Name | Dartmouth-hitchcock Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548210198 PECOS PAC ID: 4183537509 Enrollment ID: O20040809000442 |
News Archive
Do school-based interventions prevent HIV, sexually transmitted diseases and pregnancy? This is the question asked by researchers from the University of York, South African Medical Research Council and Stellenbosch University in a Cochrane review published this week.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company's strategic alliance with GlaxoSmithKline.
A collaboration of French and Canadian researchers have found that sucking a portion of a spherical globule of cells into a tiny pipette provides information about the adhesion between cells and the elastic properties of the tissue. The method is a novel approach for the study of the structural properties of tissues, and should offer insights into processes such as embryonic development, tissue growth and cancer. A paper describing the research appears online in Physical Review Letters on May 24.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Entity Name | Alliance Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891859419 PECOS PAC ID: 8022019215 Enrollment ID: O20070131000394 |
News Archive
Do school-based interventions prevent HIV, sexually transmitted diseases and pregnancy? This is the question asked by researchers from the University of York, South African Medical Research Council and Stellenbosch University in a Cochrane review published this week.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company's strategic alliance with GlaxoSmithKline.
A collaboration of French and Canadian researchers have found that sucking a portion of a spherical globule of cells into a tiny pipette provides information about the adhesion between cells and the elastic properties of the tissue. The method is a novel approach for the study of the structural properties of tissues, and should offer insights into processes such as embryonic development, tissue growth and cancer. A paper describing the research appears online in Physical Review Letters on May 24.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Harvery Turco, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-8630 | Dr John Harvery Turco, MD 1 Medical Center Dr, Lebanon, NH 03756-1000 Ph: (603) 650-8630 |
News Archive
Do school-based interventions prevent HIV, sexually transmitted diseases and pregnancy? This is the question asked by researchers from the University of York, South African Medical Research Council and Stellenbosch University in a Cochrane review published this week.
Concert Pharmaceuticals, Inc. announced today that it has initiated a Phase 1b clinical study with CTP-518, its investigational oral HIV protease inhibitor for the treatment of HIV infection. In connection with the start of this multiple ascending dose arm of the Phase 1 study, Concert will receive a $12 million milestone payment under the company's strategic alliance with GlaxoSmithKline.
A collaboration of French and Canadian researchers have found that sucking a portion of a spherical globule of cells into a tiny pipette provides information about the adhesion between cells and the elastic properties of the tissue. The method is a novel approach for the study of the structural properties of tissues, and should offer insights into processes such as embryonic development, tissue growth and cancer. A paper describing the research appears online in Physical Review Letters on May 24.
The Los Angeles Times: "The top executives at the nation's five largest for-profit health insurance companies pulled in nearly $200 million in compensation last year — while their businesses prepared to hit ratepayers with double-digit premium increases, according to a new analysis conducted by healthcare activists. The leaders of Cigna Corp., Humana Inc., UnitedHealth Group and WellPoint Inc. each in effect received raises in 2009, the report concluded, based on an analysis of company reports filed with the Security and Exchange Commission.
Octapharma AG, one of the largest manufacturers of plasma products in the world, today announced that it has received orphan drug exclusivity approval for wilate® from the U.S. Food and Drug Administration (FDA).
› Verified 5 days ago
Elias Loukas, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dhmc Section Of Hospital Medicine, Lebanon, NH 03756 Phone: 603-650-8380 | |
Dr. Michael W Winter, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Gastroenterology, Lebanon, NH 03756 Phone: 603-650-5261 | |
Hannah Elizabeth Foote Bensimhon, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5000 | |
Victoria Forbes, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5516 | |
Zanira Fazal, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 18 Old Etna Rd, Lebanon, NH 03766 Phone: 603-650-4000 | |
Susan Si-yao Wang, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Dartmouth-hitchcock Medical Ctr, Department Of Medicine, Lebanon, NH 03756 Phone: 603-650-9480 | |
Mark Edward Splaine, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Dhmc Section Of General Internal Medicine, Lebanon, NH 03756 Phone: 603-653-9500 |